Jan 23, 2019- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent- Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth- Jan 16, 2019Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment
-
Nov 15, 2018New White Paper Shares Research Findings on Perceptions and Awareness of Medical Device Cybersecurity, Need for Collaboration to Address Cybersecurity Challenges
-
Oct 17, 2018- Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent- Third-quarter GAAP EPS from continuing operations of $0.31; adjusted EPS from continuing operations of $0.75- Strong growth and pipeline advancements across portfolio
-
Oct 15, 2018- Mr. Ford, a 22-year Abbott veteran, is currently executive vice president of Medical Devices, Abbott's largest business- Mr. Ford will expand his current role, taking on responsibility for all of Abbott's operating businesses
-
Sep 13, 2018- Company achieves more than double the overall average industry score and maintains top industry scores in economic and social performance- Abbott recognized for sustainability on DJSI for 14 consecutive years
-
Aug 3, 2018Global recognition for cross-functional care teams achieving measurably better healthcareNow accepting applications to celebrate unity and change in healthcare
-
Jun 26, 2018- Two-Thirds of Millennials Aren't Saving for Retirement- Benefit Means Student Debt Won't Prevent Retirement Savings
-
May 4, 2018- Abbott previously communicated safety alert related to potential outflow graft twisting to physicians on April 5, 2018
-
Apr 17, 2018- Latest in planned series of cybersecurity updates further strengthens security and performance of implantable cardioverter defibrillators- Part of Abbott’s ongoing commitment to continuously advance the security of connected devices and systems
-
Feb 27, 2018- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U.- AGREEMENT COMPLEMENTS AND EXTENDS ABBOTT'S BROAD LINE OF VASCULAR CARE PRODUCTS AND DEMONSTRATES VALUE OF SURMODICS' PROPRIETARY DRUG-DELIVERY AND WHOLE-PRODUCT SOLUTIONS STRATEGY
-
Aug 29, 2017-Planned updates designed to provide new patient management tools and further protection against unauthorized access- Updates part of ongoing effort to continuously improve patient care
Jul 13, 2017- Agreement promises major leap forward in automation of diabetes management- Abbott will supply Bigfoot with the next generation of its FreeStyle® Libre glucose sensing technology for clinical and commercial use
Apr 26, 2017-Research shows that staying nourished in the days and hours prior to a procedure can help patients prepare for and recover from surgery- New Ensure® Surgery Immunonutrition Shake and Ensure® Pre-Surgery Clear Nutrition Drink are designed for hospitals implementing surgical guidelines for enhancing patient recovery
- Jan 25, 2017- Fourth-quarter GAAP EPS from continuing operations of $0.51; adjusted EPS from operations of $0.65- Issues EPS outlook for 2017, reflecting double-digit growth at the mid-point- Completed acquisition of St. Jude Medical, creating a premier medical device business with leading positions in several large and high-growth areas